Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular

Abstract Aim To pool the incremental net benefits (INBs) of using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treating obesity without diabetes. Materials and Methods PubMed,

JCM, Vol. 14, Pages 8734: The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis Journal

GLP-1 users are rewriting the rules of appetite, texture and indulgence. Tate & Lyle’s latest research shows exactly where producers are missing the moment.

Boxes of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes [LILLY KOREA]   Thirty-five cases of adverse reactions or serious side effects

Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients with type 2 diabetes than using GLP-1

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug,

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by certain antipsychotic medications. A randomized trial demonstrated that

Another day, another delightfully slim adidas sneaker remade in the Samba’s image. Who’s complaining? The adidas Handball Spezial Lo Pro Core shoe takes a delightfully

A month after besting rival Novo Nordisk A/S in a bidding war for obesity drug developer Metsera Inc., Pfizer Inc. is again adding to its

CNN’s Erin Burnett speaks to Eli Lilly CEO David Ricks on major changes to weight-loss drugs and expanded manufacturing. Watch the full interview on Erin

The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis. The first cat was successfully dosed in the MEOW-1

The rapid adoption of GLP-1 weight loss medications — drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro — is reshaping

Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1, orforglipron Company plans to create 3,450 manufacturing

Many women with PCOS say they struggled for years to get a diagnosis and effective treatment. Now, more are finding relief as GLP-1 prescriptions for

The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events

YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions

India and China are among the countries where knockoffs of Wegovy and Ozempic can be sold next year

A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect

Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes Diabetology doi: 10.3390/diabetology6120161 Authors: Scott

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist

ORLANDO, Fla. — Eli Lilly’s new chief dealmaker is planning to spend its GLP-1 cash in an “aggressive” but responsible manner. Last month, Lilly’s president

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion

The systematic review and meta-analysis of 48 trials involving 94,245 individuals show little or no effect of GLP-1 RA treatment on the risk for obesity-related

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, today announced the launch of two studies to

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai

Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered

On Nov. 19, Pfizer CFO Dave Denton said at the Jefferies Global Healthcare Conference that the large pharma was still looking for an oral small

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light. Medscape Medical News

College students may seek you out over winter break wanting to start a GLP-1. Medscape Medical News

Food Funct., 2026, Accepted ManuscriptDOI: 10.1039/D5FO03164H, Paper Jiaomei Li, Hao Wang, Jiekai Yang, Yicheng Wang, Guo Jia, Jiaojiao Gu1,3-Diacylglycerol (1,3-DAG) is a dietary lipid with

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests.

The rise in the use of GLP-1 weight-loss drugs across the U.S. is shifting not only scales, but also how Americans are spending their time

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D)

(NaturalNews) A large-scale study of over 1.2 million patients found that more than half (58%) of those who stop GLP-1 weight-loss drugs like Wegovy and

Federal Trade Commission crackdown on company selling GLP-1 is a reminder of the dangers consumers face when purchasing trending treatments online